Virbac S.A. stock (FR0000031577): Animal health specialist updates outlook after strong 2024 results

Virbac S.A., the French animal health group, has updated its 2025 outlook after reporting solid 2024 results, drawing fresh attention from investors to its expanding pet and livestock portfolio and global footprint.

Virbac S.A., the French animal health company, drew renewed investor attention after publishing strong full-year 2024 results in March and updating its 2025 outlook, including new margin ambitions and continued investment in capacity and innovation, according to a company press release dated 03/20/2025 and full-year documentation released the same day Virbac press release as of 03/20/2025.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Virbac
• Sector/industry: Animal health, pharmaceuticals
• Headquarters/country: Carros, France
• Core markets: Companion animals and food-producing animals worldwide
• Key revenue drivers: Veterinary medicines, vaccines and nutritional products for pets and livestock
• Home exchange/listing venue: Euronext Paris (ticker: VIRP)
• Trading currency: Euro (EUR)

Virbac S.A.: core business model

Virbac focuses exclusively on animal health, developing, manufacturing and marketing products for both companion animals and food-producing animals. The company’s portfolio includes vaccines, parasiticides, antibiotics, dermatology treatments and nutritional supplements that veterinarians prescribe or recommend, according to its corporate overview and annual documentation published in March 2025 Virbac company profile as of 03/20/2025.

The group operates a B2B-centric model, selling primarily to veterinarians, clinics, distributors and certain retail channels, rather than directly to end consumers. Its revenue base is geographically diversified across Europe, the Americas and Asia-Pacific, limiting dependence on a single market and exposing the company to global animal health trends, according to its 2024 annual results communication published on 03/20/2025 Virbac 2024 results release as of 03/20/2025.

Virbac positions itself as a specialist mid-sized player compared with diversified pharmaceutical giants that also operate in animal health. Its strategy emphasizes targeted R&D, a wide yet focused product range, and strong local presence in key veterinary markets. This combination allows the company to respond to differing regulatory and therapeutic needs across regions while leveraging global platforms for manufacturing and quality control.

Main revenue and product drivers for Virbac S.A.

Companion animal products have become an increasingly important growth engine for Virbac. The company has highlighted continued momentum in treatments for dogs and cats, including parasiticides and dermatology products, supported by rising pet ownership and higher spending on pet healthcare in many regions, according to its commentary on the 2024 full-year performance released on 03/20/2025 Virbac 2024 results release as of 03/20/2025.

Livestock products remain a significant part of the business, particularly in emerging markets where demand is shaped by herd health, productivity and food safety regulations. Virbac offers vaccines, antiparasitics and anti-infectives that support cattle, swine and poultry producers. These segments can be sensitive to agricultural cycles and regulatory changes, but they also benefit from long-term structural trends such as protein consumption growth and disease prevention initiatives.

Virbac also invests in specialty products and services that can support long-term customer relationships, such as diagnostics, nutritional solutions and digital tools for veterinary practices. While these may represent smaller revenue lines than core medicines, they can contribute to differentiation and cross-selling opportunities. The interplay between core prescription products and complementary offerings is an important factor in the company’s ability to maintain margins and capture value along the veterinary care chain.

Conclusion

Virbac S.A. offers US and international investors exposure to the global animal health sector through a pure-play listed on Euronext Paris. The company’s updated outlook following strong 2024 results underlines its intention to balance growth investments with profitability. At the same time, Virbac remains exposed to regulatory, competitive and agricultural-cycle risks inherent to the sector. For investors following healthcare and pet-care themes from the United States, the stock may serve as a way to track European innovation and demand dynamics in veterinary medicine without direct exposure to the US large-cap pharmaceutical universe.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.